(Q33895157)

29 July 2017

1 reference

title

Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters (English)

1 reference

29 July 2017

1 reference

1 reference

Pickerill KE

1

1 reference

29 July 2017

Paladino JA

series ordinal

2

1 reference

29 July 2017

Schentag JJ

series ordinal

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

29 July 2017

1 reference

29 July 2017

20

1 reference

29 July 2017

4

1 reference

29 July 2017

417-428

1 reference

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

29 July 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

In vitro activity of the new fluoroquinolone CP-99,219.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Pharmacokinetics of ofloxacin after parenteral and oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Ofloxacin: serum and skin blister fluid pharmacokinetics in the fasting and non-fasting state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

The clinical pharmacokinetics of levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.5.417.35062

10.1592/PHCO.20.5.417.35062

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference